How does a history of keloid or hypertrophic scarring affect a filler decision?

Some dermal filler labeling states that safety has not been adequately evaluated in people prone to keloid or hypertrophic scars. A deep filler injection is not identical to a surface scar, but abnormal scarring history, active skin disease, planned punctures, material and no treatment need careful review.

This translation has no recorded clinical or medical-language review.

Direct answer

A keloid tendency should not be assumed from the statement that a scar healed badly.
A small needle opening does not eliminate the possibility of a nodule or foreign-body response.
Lack of controlled evidence should be interpreted as neither automatic safety nor an automatic prohibition.

Define the scar history first

A keloid grows beyond the original wound boundaries, whereas a hypertrophic scar generally remains within them. Record site, trigger, onset, prior treatment and family history. An acne nodule, filler nodule or infection scar can be mistaken for these diagnoses, and dermatology assessment may be needed before an elective procedure.

What uncertainties does filler add?

A needle or cannula crosses the skin barrier and implant material persists for varying periods. Product labeling may describe safety as unknown in people prone to excessive scarring. That does not show identical risk for every filler; material, depth, area, number of punctures and previous foreign-body reactions matter separately.

Decision and follow-up plan

When elective benefit is limited, postponement or no procedure are reasonable. If treatment is considered, document the exact product, volume, area and lot, and define contact instructions for early infection signs or a firm raised lesion emerging weeks to months later. Treating every lump as a scar with steroids can delay diagnosis of infection or a filler nodule.

Scope of this article

This content is not diagnosis, prescribing, personal risk assessment or a treatment plan. Sources may be limited to a particular product, device, task, indication or study group.

Sources and evidence limits

These links are editorial starting points used to examine the article's boundaries.

Dermal Fillers (Soft Tissue Fillers)
U.S. Food and Drug Administration (FDA) · 2023
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Guideline for the Management of Hyaluronic Acid Filler-Induced Vascular Occlusion
Gillian Murray, Cormac Convery, Lee Walker, Emma Davies; Complications in Medical Aesthetics Collaborative (CMAC) · 2021
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Safety and Potential Complications of Facial Wrinkle Correction with Dermal Fillers: A Systematic Literature Review
Audra Janovskiene, Deividas Chomicius, Dominykas Afanasjevas, Zygimantas Petronis, Dainius Razukevicius, Egle Jagelaviciene · 2024
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Belotero Volume (+) Lidocaine — Prescribing Information and Instructions for Use
FDA device labeling / Merz North America · 2026
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review
Late-Onset Reactions after Hyaluronic Acid Dermal Fillers: A Consensus Recommendation
CARE board consensus authors · 2024
Scope and limitations: Interpret this source only within the exact product, device, method, indication and study population it names. It does not establish personal suitability, Turkish authorization, a universal protocol or a guaranteed outcome; consult the full source and current local information.
Editorial source — not a signed clinical review